ArticlePediatric rheumatology online journal2026
Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to examine the clinical characteristics, triggers and risk factors for gastrointestinal (GI) complications in anti-NXP2-positive JDM (anti-NXP2-JDM) patients.
methodsA retrospective analysis was performed on 57 anti-NXP2-JDM patients, including 19 with severe GI complications (GI group) and 38 without GI involvement (Non-GI group).
resultsThe GI group had a male-to-female ratio of 6:13 and a mean onset age of 5.83 years, with abdominal pain as the most common initial symptom. All severe GI involvement occurred during active JDM, and 16 patients (84%) had prodromal infections (potential triggers). Compared with the Non-GI group, the GI group showed significantly lower proximal muscle strength grade, CMAS score, BMI, hemoglobin, albumin, creatinine and lymphocyte count, and higher rates of severe JDM at onset, malnutrition, infection, skin ulcer, edema, livedo reticularis. The GI groups also had higher CAT-A score, CAT-D score, WBC, CRP, ESR, ferritin and LDH. Multivariate analysis identified severe JDM at onset, infection, malnutrition, CAT-A score, skin ulcer, edema and ESR as independent risk factors for GI complications, and lymphocyte count, proximal muscle strength, CMAS score, hemoglobin and albumin as protective factors. Kaplan-Meier analysis showed significantly different survival rates between groups. The proportion of deaths was 26.3% (5/19) in the GI group compared to 0% (0/38) in the non-GI group (p = 0.002).
conclusionsAnti-NXP2-JDM patients require vigilant monitoring and early intervention to mitigate GI complications and improve outcomes. Infection may be an important trigger. Risk factors for GI complications include severe JDM at onset, malnutrition, skin ulceration, edema, low CMAS score, high CAT-A score, lymphocytopenia, anemia, hypoalbuminemia and elevated ESR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.